Letrozol Glenmark

Letrozole, the active ingredient in Letrozol Glenmark, is an aromatase inhibitor presented as a tablet for oral use. It is used to treat postmenopausal estrogen receptor‑positive breast cancer by lowering estrogen levels in the body.

GNH USA supplies Letrozol Glenmark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Letrozol Glenmark is an aromatase inhibitor indicated for hormone‑driven breast cancer conditions. - Postmenopausal estrogen receptor‑positive breast cancer: reduces tumor growth by decreasing estrogen synthesis. - Adjuvant therapy for early‑stage hormone‑receptor‑positive breast cancer: lowers risk of disease recurrence. - Advanced or metastatic breast cancer in postmenopausal women: helps control disease progression.

Letrozol Glenmark may cause a range of adverse reactions, which vary in frequency and severity.

Common Side Effects: - Hot flashes: sudden feeling of warmth, often with sweating. - Joint and muscle pain: aching or stiffness in joints or muscles. - Fatigue: persistent tiredness not relieved by rest. - Nausea: feeling of queasiness or urge to vomit. - Headache: mild to moderate head pain. - Dizziness: sensation of light‑headedness or unsteadiness.

Serious or Rare Side Effects: - Severe liver injury: jaundice, dark urine, or elevated liver enzymes. - Bone fracture: increased risk due to reduced bone mineral density. - Pulmonary embolism: sudden shortness of breath, chest pain. - Deep vein thrombosis: swelling, pain in a leg. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Cardiac arrhythmia: abnormal heart rhythm, including QT prolongation.

Before initiating Letrozol Glenmark, clinicians should consider several safety measures. - Bone health monitoring: assess baseline bone density and consider calcium/vitamin D supplementation. - Liver function assessment: obtain baseline liver enzymes and monitor periodically. - Cardiovascular risk evaluation: review history of thromboembolic events or heart disease. - Hypersensitivity screening: avoid use in patients with known allergy to letrozole or excipients. - Store at ambient temperature: keep below 25°C, in the original packaging, protected from moisture.

Letrozol Glenmark can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Estrogen replacement therapy: antagonizes letrozole’s estrogen‑lowering effect. - Strong CYP2A6 inhibitors (e.g., fluvoxamine): may increase letrozole plasma concentrations. - Concurrent use with tamoxifen: opposing mechanisms may reduce therapeutic benefit.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower letrozole levels, reducing efficacy. - Warfarin: letrozole may enhance anticoagulant effect, requiring INR monitoring. - Selective serotonin reuptake inhibitors (SSRIs): potential modest impact on metabolism; observe for altered response.